Every public signal F4 has attached to this firm, with sources and cross-entity links.
Team Change
Fernando Carranza joined Chingona Ventures as Senior Principal. He previously spent three years at Cleveland Avenue and is a Kauffman Fellow. His joining announcement mentions the firm is building Fund III.
Chingona Ventures published its 2025 Year in Review, detailing $9M deployed across 7 new portfolio companies, 1,700+ deals reviewed, portfolio milestones including Teal Health FDA approval, EarlyBird acquisition by Acorns, and Agency $20M Series A.
Portfolio company Teal Health received FDA approval for its at-home cervical cancer screening device and raised $10M additional capital led by Emerson Collective and Forerunner.
Portfolio company Certiverse announced an $11M Series A round led by Cherryrock Capital; Chingona holds a board seat since pre-product investment in 2020.